Long-term complications with prostate implants: iodine-125 vs. palladium-103

Area of Science:

• Oncology
• Medical Physics
• Radiotherapy

Background:

• Prostate cancer brachytherapy commonly uses Iodine-125 (I-125) and Palladium-103 (Pd-103) isotopes.
• The linear quadratic model predicts differences in biologically effective dose (BED) and complication rates between I-125 and Pd-103.
• Current prescribed minimum tumor doses (MTD) for I-125 (160 Gy) and Pd-103 (115 Gy) are used in brachytherapy.

Purpose of the Study:

• To compare the normal tissue complication rates between Pd-103 and I-125 prostate brachytherapy.
• To evaluate the radiobiological effectiveness of Pd-103 versus I-125 in terms of tumor cell kill.
• To explore future research directions for prostate brachytherapy implants.

Main Methods:

• Utilized the linear quadratic model to predict BED for Pd-103 and I-125.
• Reviewed clinical data from 123 early-stage prostate cancer patients treated at Yale University (82 with I-125, 41 with Pd-103).
• Conducted a literature review of 992 patients treated with I-125 versus 540 patients treated with Pd-103.

Main Results:

• Pd-103 brachytherapy demonstrated significantly lower overall complication rates (0%) compared to I-125 (13%).
• Grade III-IV complication rates were 0% for Pd-103 versus 6% for I-125.
• The 3-year complication-free survival was 100% for Pd-103 compared to 82% for I-125 (P<0.01).
• Literature review consistently showed higher complication rates with I-125 than Pd-103.
• Radiobiological modeling predicts greater log10 cell kill for Pd-103, even with equivalent normal tissue BED.

Conclusions:

• Pd-103 prostate brachytherapy is associated with a superior safety profile and lower complication rates compared to I-125.
• Pd-103 may offer enhanced tumoricidal effect, supporting its use in prostate cancer treatment.
• Further research should investigate optimizing Pd-103 dosing for maximal efficacy and minimal toxicity.